Literature DB >> 21430652

Fluoxetine, desipramine, and the dual antidepressant milnacipran reduce alcohol self-administration and/or relapse in dependent rats.

Emmanuelle Simon O'Brien1, Rémi Legastelois, Hakim Houchi, Catherine Vilpoux, Stéphanie Alaux-Cantin, Olivier Pierrefiche, Etienne André, Mickaël Naassila.   

Abstract

A few clinical studies have shown that dual antidepressants (serotonergic (5-HT) and noradrenergic (NE) transporter inhibitors, SNRIs) may be effective in alcoholism treatment. We studied the effect of the dual antidepressant milnacipran on ethanol operant self-administration in acutely withdrawn ethanol-dependent and in -non-dependent Wistar rats, and used fluoxetine and desipramine to dissect both 5-HT and NE components, respectively, in the effect of milnacipran. Milnacipran was also tested for relapse after protracted abstinence and on ethanol-induced (1.0 g/kg) conditioned place preference in control rats and ethanol-induced locomotor sensitization in DBA/2J female mice. Milnacipran dose dependently (5-40 mg/kg) attenuated the increased ethanol self-administration observed during early withdrawal and was more potent in preventing reinstatement in dependent rats after protracted abstinence as compared with non-dependent rats. Desipramine and fluoxetine (10 mg/kg) blocked ethanol self-administration during early withdrawal, and recovery was delayed in dependent animals, indicating a potent effect. Ethanol self-administration was also reduced 1 day after treatment with desipramine and fluoxetine but not with milnacipran. Finally, milnacipran prevented ethanol-induced place preference in ethanol-naive rats and reduced the magnitude of ethanol-induced sensitization associated with a delayed induction in mice. Desipramine (20 mg/kg) countered sensitization development and reduced its expression at 1 week after treatment; fluoxetine (10 mg/kg) reduced sensitization expression. Thus, 5-HT and NE transmissions during sensitization expression may mediate the effect of milnacipran on sensitization induction. These results support that SNRIs may have a potential use in alcoholism treatment.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21430652      PMCID: PMC3096819          DOI: 10.1038/npp.2011.37

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  70 in total

1.  Norepinephrine uptake sites in the locus coeruleus of rat lines selectively bred for high and low alcohol preference: a quantitative autoradiographic binding study using [3H]-tomoxetine.

Authors:  B H Hwang; G M Wang; D T Wong; L Lumeng; T K Li
Journal:  Alcohol Clin Exp Res       Date:  2000-05       Impact factor: 3.455

2.  Mirtazapine and venlafaxine in the management of collateral psychopathology during alcohol detoxification.

Authors:  John Liappas; Thomas Paparrigopoulos; Elias Tzavellas; Andreas Rabavilas
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2004-11-23       Impact factor: 5.067

3.  Effect of acute and daily cocaine treatment on extracellular dopamine in the nucleus accumbens.

Authors:  P W Kalivas; P Duffy
Journal:  Synapse       Date:  1990       Impact factor: 2.562

4.  Manipulation of operant responding for an ethanol-paired conditioned stimulus in the rat by pharmacological alteration of the serotonergic system.

Authors:  A W Wilson; B Costall; J C Neill
Journal:  J Psychopharmacol       Date:  2000       Impact factor: 4.153

5.  Excessive ethanol drinking following a history of dependence: animal model of allostasis.

Authors:  A J Roberts; C J Heyser; M Cole; P Griffin; G F Koob
Journal:  Neuropsychopharmacology       Date:  2000-06       Impact factor: 7.853

6.  Parametric analysis of the development and expression of ethanol-induced behavioral sensitization in female Swiss mice: effects of dose, injection schedule, and test context.

Authors:  Vincent Didone; Caroline Quoilin; Ezio Tirelli; Etienne Quertemont
Journal:  Psychopharmacology (Berl)       Date:  2008-08-07       Impact factor: 4.530

7.  Behavioral sensitization: characterization of enduring changes in rotational behavior produced by intermittent injections of amphetamine in male and female rats.

Authors:  T E Robinson
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

8.  Effect of prepubertal ovariectomy on amphetamine-induced locomotor activity in adult female rats.

Authors:  M L Forgie; J Stewart
Journal:  Horm Behav       Date:  1994-09       Impact factor: 3.587

9.  Effects of acute and repeated ethanol exposures on the locomotor activity of BXD recombinant inbred mice.

Authors:  T J Phillips; M Huson; C Gwiazdon; S Burkhart-Kasch; E H Shen
Journal:  Alcohol Clin Exp Res       Date:  1995-04       Impact factor: 3.455

10.  Enhanced alcohol self-administration after intermittent versus continuous alcohol vapor exposure.

Authors:  Laura E O'Dell; Amanda J Roberts; Ron T Smith; George F Koob
Journal:  Alcohol Clin Exp Res       Date:  2004-11       Impact factor: 3.455

View more
  20 in total

Review 1.  An Animal Model of Alcohol Dependence to Screen Medications for Treating Alcoholism.

Authors:  H C Becker; M F Lopez
Journal:  Int Rev Neurobiol       Date:  2016-03-10       Impact factor: 3.230

2.  Adolescent social isolation increases anxiety-like behavior and ethanol intake and impairs fear extinction in adulthood: Possible role of disrupted noradrenergic signaling.

Authors:  M J Skelly; A E Chappell; E Carter; J L Weiner
Journal:  Neuropharmacology       Date:  2015-06-01       Impact factor: 5.250

3.  Triple monoamine uptake inhibitors demonstrate a pharmacologic association between excessive drinking and impulsivity in high-alcohol-preferring (HAP) mice.

Authors:  David S O'Tousa; Kaitlin T Warnock; Liana M Matson; Ojas A Namjoshi; Michael Van Linn; Veera Venkata Tiruveedhula; Meredith E Halcomb; James Cook; Nicholas J Grahame; Harry L June
Journal:  Addict Biol       Date:  2013-10-13       Impact factor: 4.280

Review 4.  Neurochemical mechanisms of alcohol withdrawal.

Authors:  Howard C Becker; Patrick J Mulholland
Journal:  Handb Clin Neurol       Date:  2014

Review 5.  Evidence for incentive salience sensitization as a pathway to alcohol use disorder.

Authors:  Roberto U Cofresí; Bruce D Bartholow; Thomas M Piasecki
Journal:  Neurosci Biobehav Rev       Date:  2019-10-28       Impact factor: 8.989

6.  Effects of the triple monoamine uptake inhibitor DOV 102,677 on alcohol-motivated responding and antidepressant activity in alcohol-preferring (P) rats.

Authors:  Andrew R S T Yang; Heon S Yi; Kaitlin T Warnock; Jacek Mamczarz; Harry L June; Nikhil Mallick; Philip A Krieter; Leonardo Tonelli; Phil Skolnick; Anthony S Basile; Harry L June
Journal:  Alcohol Clin Exp Res       Date:  2011-12-07       Impact factor: 3.455

7.  Cessation of fluoxetine treatment increases alcohol seeking during relapse and dysregulates endocannabinoid and glutamatergic signaling in the central amygdala.

Authors:  Juan Suárez; Sophia Khom; Francisco Alén; Luis A Natividad; Florence P Varodayan; Reesha R Patel; Dean Kirson; Rocío Arco; Antonio Ballesta; Michal Bajo; Leticia Rubio; Rémi Martin-Fardon; Fernando Rodríguez de Fonseca; Marisa Roberto
Journal:  Addict Biol       Date:  2019-07-24       Impact factor: 4.280

8.  Amitifadine, a triple monoamine uptake inhibitor, reduces binge drinking and negative affect in an animal model of co-occurring alcoholism and depression symptomatology.

Authors:  Kaitlin T Warnock; Andrew R S T Yang; Heon S Yi; Harry L June; Timothy Kelly; Anthony S Basile; Phil Skolnick; Harry L June
Journal:  Pharmacol Biochem Behav       Date:  2012-11       Impact factor: 3.533

9.  Effects of iloperidone, combined with desipramine, on alcohol drinking in the Syrian golden hamster.

Authors:  Jibran Y Khokhar; Alan I Green
Journal:  Neuropharmacology       Date:  2016-01-12       Impact factor: 5.250

10.  Desipramine enhances the ability of paliperidone to decrease alcohol drinking.

Authors:  David T Chau; Jibran Y Khokhar; Danielle Gulick; Ree Dawson; Alan I Green
Journal:  J Psychiatr Res       Date:  2015-07-18       Impact factor: 4.791

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.